AI
CRSP icon

AXS Investments’s CRISPR Therapeutics CRSP Stock Holding History

AXS Investments’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,035
Closed -$114K – 385
2023
Q2 		$114K Hold
2,035
– – 0.03% 294
2023
Q1 		$92K Buy
+2,035
New +$98.8K 0.03% 265

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AXS Investments's CRSP Position: Q3 2023 in Review

AXS Investments sold out of CRISPR Therapeutics (CRSP) in Q3 2023, closing a stake of 2,035 shares — an estimated $114K sold.

AXS Investments first reported a position in CRSP in Q1 2023 and held it in 2 quarters. The position peaked at $114K in Q2 2023. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

  • AXS Investments reported no remaining CRISPR Therapeutics position as of Q3 2023 after selling out during the quarter.
  • AXS Investments sold 2,035 CRISPR Therapeutics shares in Q3 2023, an estimated $114K.
  • AXS Investments first reported a position in CRISPR Therapeutics in Q1 2023 and held it in 2 quarters.
  • AXS Investments's CRISPR Therapeutics position peaked at $114K in Q2 2023.
  • 406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on AXS Investments's 13F filing for Q3 2023, filed 9 Nov 2023.